TX HB2529 | 2023-2024 | 88th Legislature

Status

Spectrum: Partisan Bill (Democrat 1-0)
Status: Introduced on February 21 2023 - 25% progression, died in committee
Action: 2023-05-01 - Left pending in committee
Pending: House Public Health Committee
Text: Latest bill text (Introduced) [HTML]

Summary

Relating to written notification provided by drug manufacturers regarding the cause of generic insulin prescription drug unavailability.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Relating to written notification provided by drug manufacturers regarding the cause of generic insulin prescription drug unavailability.

Sponsors


History

DateChamberAction
2023-05-01HouseLeft pending in committee
2023-05-01HouseTestimony taken/registration(s) recorded in committee
2023-05-01HouseConsidered in public hearing
2023-05-01HouseScheduled for public hearing on . . .
2023-03-13HouseReferred to Public Health
2023-03-13HouseRead first time
2023-02-21HouseFiled

Same As/Similar To

SB241 (Same As) 2023-05-27 - Effective on . . . . . . . . . . . . . . . September 1, 2024
SB241 (Same As) 2023-05-27 - Effective on . . . . . . . . . . . . . . . September 1, 2024

Subjects


Texas State Sources


Bill Comments

feedback